NCT06249048View on ClinicalTrials.gov

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2028

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

STX-001

STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.

BIOLOGICAL

Keytruda®

Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.

Trial Locations (4)

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

90212

RECRUITING

NextGen Oncology, Beverly Hills

Unknown

RECRUITING

Melanoma Institute Australia, Wollstonecraft

All Listed Sponsors
lead

Strand Therapeutics Inc.

INDUSTRY